Pharma Industry Unites With Academia to Tackle Ongoing Problem

LONDON, October 28, 2011 /PRNewswire/ –

Leading academic and industry specialists to meet in Amsterdam next
February to discuss the challenges that could see R&D grind to a halt and
the newest ways to tackle them

Selecting and screening the correct polymorphs and ensuring the
characterisation of the co-crystals in the most efficient and effective way
has never been more vital. According to George Tranter from Chiralabs,
“Crystallisation is one of the biggest problems of the pharmaceutical
industry”.

The 8th Annual Polymorphism and Crystallisation speaker panel will be
dedicated to presenting the cutting edge technologies and techniques of
getting the pharmaceutical product to the market whilst overcoming the
problems of polymorphism.

According to an Engineer article “Co-crystallisation could speed up drug
production” (5th September), scientists have started seeking to understand
the science behind this process. However, co-crystallisation requires
particular attention to considerations like availability and quality of
drugs, waste streams generated and batch performance. Pharma IQ’s
Polymorphism and Crystallisation speakers will provide an insight into these
issues live only on 28th and 29th February in Amsterdam. Case studies will
be presented by the likes of Eli Lily, UCB Pharma and Novartis-MIT Centre
for Continuous Manufacturing, and a fantastic interactive workshop will be
run by an EPO representative.

Pharma IQ’s summit will be dedicated to delivering cutting edge insights
into areas such as:

        - Best timing and depth for a polymorphic screen during
          pharmaceutical development
        - Characterisation of co-crystals and selection of tools for
          correct characterisation tests
        - Polymorphic scale up
        - Application of PAT and QbD in pharmaceutical processes
        - Patenting of new polymorphs

At Polymorphism and Crystallisation, attendees will hear best practices
from the big industry names like GlaxoSmithKline, Merck, AstraZeneca,
Johnson and Johnson, Continuous Manufacturing and Crystallisation (CMAC),
together with leading academic institutions like University of Loughborough,
University of Leeds, University of Rouen, and more.

The full agenda, podcast, articles and interviews, are available on:

http://www.polyandcrys.com/PRNW/Event

The LinkedIn Group is open and welcomes anybody in topic and event
related discussions:

http://www.linkedin.com/groups?home=&gid=1781786&trk=anet_ug_hm

        Find the full program, event details and registration information on
        Polymorphism and Crystallisation 2012:
        Visit:  http://www.polyandcrys.com/PRNW/Event
        Email  enquire@iqpc.co.uk
        Call: +44(0)207-368-9300

        Media contact: Gergana Stoyanova
        Tel: +44(0)2073689865
        email:  Gergana.Stoyanova@iqpc.co.uk
        website:  http://www.pharma-iq.com

SOURCE Pharma IQ